Radioactive drug safety tracked for years in rare cancer patients
Knowledge-focused
Completed
This study follows 20 people with neuroendocrine tumors who previously received a radioactive drug called 177Lu-satoreotide tetraxetan. Researchers check for long-term side effects, including new cancers, every 3 months for up to 5 years. The goal is to understand the drug's safe…
Phase: NA • Sponsor: Ariceum Therapeutics GmbH • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:29 UTC